Literature DB >> 11163240

The cytoplasmic domain of the ligand ephrinB2 is required for vascular morphogenesis but not cranial neural crest migration.

R H Adams1, F Diella, S Hennig, F Helmbacher, U Deutsch, R Klein.   

Abstract

The transmembrane ligand ephrinB2 and its cognate Eph receptor tyrosine kinases are important regulators of vascular morphogenesis. EphrinB2 may have an active signaling role, resulting in bi-directional signal transduction downstream of both ephrinB2 and Eph receptors. To separate the ligand and receptor-like functions of ephrinB2 in mice, we replaced the endogenous gene by cDNAs encoding either carboxyterminally truncated (ephrinB2(DeltaC)) or, as a control, full-length ligand (ephrinB2(WT)). While homozygous ephrinB2(WT/WT) animals were viable and fertile, loss of the ephrinB2 cytoplasmic domain resulted in midgestation lethality similar to ephrinB2 null mutants (ephrinB2(KO)). The truncated ligand was sufficient to restore guidance of migrating cranial neural crest cells, but ephrinB2(DeltaC/DeltaC) embryos showed defects in vasculogenesis and angiogenesis very similar to those observed in ephrinB2(KO/KO) animals. Our results indicate distinct requirements of functions mediated by the ephrinB carboxyterminus for developmental processes in the vertebrate embryo.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11163240     DOI: 10.1016/s0092-8674(01)00191-x

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  82 in total

Review 1.  Molecular control of arterial-venous blood vessel identity.

Authors:  Ralf H Adams
Journal:  J Anat       Date:  2003-01       Impact factor: 2.610

Review 2.  Cellular and molecular mechanisms of embryonic haemangiogenesis and lymphangiogenesis.

Authors:  Jörg Wilting; Bodo Christ; Li Yuan; Anne Eichmann
Journal:  Naturwissenschaften       Date:  2003-09-17

Review 3.  Control of neural crest cell behavior and migration: Insights from live imaging.

Authors:  Matthew R Clay; Mary C Halloran
Journal:  Cell Adh Migr       Date:  2010 Oct-Dec       Impact factor: 3.405

Review 4.  Regional differences in neural crest morphogenesis.

Authors:  Bryan R Kuo; Carol A Erickson
Journal:  Cell Adh Migr       Date:  2010 Oct-Dec       Impact factor: 3.405

5.  EphB-ephrin-B2 interactions are required for thymus migration during organogenesis.

Authors:  Katie E Foster; Julie Gordon; Kim Cardenas; Henrique Veiga-Fernandes; Taija Makinen; Elena Grigorieva; David G Wilkinson; C Clare Blackburn; Ellen Richie; Nancy R Manley; Ralf H Adams; Dimitris Kioussis; Mark C Coles
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-08       Impact factor: 11.205

6.  PDZ interaction site in ephrinB2 is required for the remodeling of lymphatic vasculature.

Authors:  Taija Mäkinen; Ralf H Adams; John Bailey; Qiang Lu; Andrew Ziemiecki; Kari Alitalo; Rüdiger Klein; George A Wilkinson
Journal:  Genes Dev       Date:  2005-02-01       Impact factor: 11.361

7.  EphB4 controls blood vascular morphogenesis during postnatal angiogenesis.

Authors:  Ralf Erber; Uta Eichelsbacher; Violetta Powajbo; Tobias Korn; Valentin Djonov; Jihong Lin; Hans-Peter Hammes; Rainer Grobholz; Axel Ullrich; Peter Vajkoczy
Journal:  EMBO J       Date:  2006-01-19       Impact factor: 11.598

8.  Ephrin-B2 governs morphogenesis of endolymphatic sac and duct epithelia in the mouse inner ear.

Authors:  Steven Raft; Leonardo R Andrade; Dongmei Shao; Haruhiko Akiyama; Mark Henkemeyer; Doris K Wu
Journal:  Dev Biol       Date:  2014-02-26       Impact factor: 3.582

9.  Neural crest defects in ephrin-B2 mutant mice are non-autonomous and originate from defects in the vasculature.

Authors:  Ace E Lewis; Jennifer Hwa; Rong Wang; Philippe Soriano; Jeffrey O Bush
Journal:  Dev Biol       Date:  2015-09-16       Impact factor: 3.582

10.  EphrinB2 reverse signaling protects against capillary rarefaction and fibrosis after kidney injury.

Authors:  Yujiro Kida; Nicholas Ieronimakis; Claudia Schrimpf; Morayma Reyes; Jeremy S Duffield
Journal:  J Am Soc Nephrol       Date:  2013-03-14       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.